Medicine and Dentistry
Prospective Study
100%
Chronic Urticaria
100%
Omalizumab
100%
Patient-Reported Outcome
100%
Quality of Life
28%
Diseases
28%
Histamine Antagonist
28%
Urticaria
14%
Treatment Effect
14%
Azathioprine
14%
Methotrexate
14%
Randomized Controlled Trial
14%
Side Effect
14%
Treatment Response
14%
Disease Activity
14%
Immunosuppressive Drug
14%
Clinical Management
14%
Cyclosporine
14%
Immunoglobulin E
14%
Keyphrases
Patient-reported Outcomes
100%
Omalizumab
100%
Chronic Spontaneous Urticaria
100%
Antihistamines
28%
Previous Treatment
14%
University Departments
14%
Disease Activity
14%
Urticaria Activity Score
14%
Disease Control
14%
Patient Characteristics
14%
Treatment Response
14%
Quality of Life
14%
Cyclosporine
14%
Patient Identification
14%
Treatment Effect
14%
Anti-IgE
14%
Effective Therapy
14%
Strong Correlation
14%
Highly Effective
14%
Patient-specific
14%
Randomized Controlled Trial
14%
Methotrexate
14%
Clinical Management
14%
Disease-specific Quality of Life
14%
Pharmacology, Toxicology and Pharmaceutical Science
Omalizumab
100%
Chronic Urticaria
100%
Prospective Study
100%
Antihistaminic Agent
28%
Diseases
28%
Randomized Controlled Trial
14%
Immunosuppressive Agent
14%
Urticaria
14%
Azathioprine
14%
Side Effect
14%
Ciclosporin
14%
Methotrexate
14%
Disease Activity
14%
Immunoglobulin E
14%
Neuroscience
Antihistamines
28%
Methotrexate
14%
Azathioprine
14%
Immunosuppressive Drug
14%
Ciclosporin
14%
Randomized Controlled Trial
14%
Immunoglobulin E
14%